U.S. markets close in 3 hours 17 minutes

Novavax, Inc. (NVAX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
5.70-0.03 (-0.61%)
As of 12:42PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close5.73
Bid5.67 x 1000
Ask5.68 x 1100
Day's Range5.66 - 5.93
52 Week Range5.30 - 18.55
Avg. Volume8,672,506
Market Cap676.509M
Beta (5Y Monthly)1.73
PE Ratio (TTM)N/A
EPS (TTM)-6.23
Earnings DateFeb 26, 2024 - Mar 01, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.60
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for NVAX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Novavax, Inc.
    Daily – Vickers Top Buyers & Sellers for 04/05/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    2 years agoArgus Research
View more
  • Investor's Business Daily

    Is Novavax Stock A Buy After WHO Signs Off On Its Updated Covid Booster?

    Novavax stock is on the rise after the World Health Organization signed off on its Covid shot. Is NVAX stock a buy or a sell right now?

  • Reuters

    UPDATE 2-WHO authorizes emergency use of Novavax's updated COVID shot

    Novavax's updated vaccine has been granted emergency-use authorization by the World Health Organization (WHO) for active immunization to prevent COVID-19 in individuals aged 12 and older, the company said on Tuesday. The updated Novavax shot, which was authorized in the U.S. last month, targets a descendant of the XBB lineage of the coronavirus that was globally predominant earlier this year. The emergency use listing helps speed up the regulatory approvals to import and administer the vaccines by member states, according to the WHO.

  • PR Newswire

    Novavax's Updated Protein-based COVID-19 Vaccine Now an Option for All 194 Member States of the World Health Organization

    Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that Nuvaxovid™ XBB.1.5 COVID-19 Vaccine (NVX-CoV2601) has been granted Emergency Use Listing (EUL) by the World Health Organization (WHO) for active immunization to prevent COVID-19 in individuals aged 12 and older. The EUL assists WHO member states in assessing vaccines with the aim of expediting availability and enables the WHO's 194 member states to expedite regulatory